RADXRadiopharm Theranostics Ltd - ADR

Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term clinical catalysts during a presentation at the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference. Chief Executive Officer Riccardo Canevari described the compa...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was...

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the four analysts that are presently covering...

(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) to diagnose suspected recurrent brain metastases from solid tumors...

Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company's ongoing Phase IIb study of RAD101, a PET imaging tracer intended to...

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are covering the firm...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there...

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are currently covering the stock...